Comparison of the effect of different methods of cyclosporine infusion on transplant-related outcomes in allogeneic transplant recipients

Engle JA Wasko JA Rogosheske J , et al. Comparison of continuous versus intermittent infusion cyclosporine and impact on transplant related outcomes in allogeneic transplant recipients. J Oncol Pharm Pract 2020. Epub ahead of print 2 November 2020. DOI: 10.1177/1078155220970608.

Hahn T McCarthy Jr PL Zhang M-J , et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen–identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26: 5728–5734.

Xhaard A Porcher R Chien JW , et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008; 22: 2062–2069.

Ah Y-M Kim Y-M Kim M-J , et al. Drug-induced hyperbilirubinemia and the clinical influencing factors. Drug Metab Rev 2008; 40: 511–537.

McDonald GB. Hepatobiliary complications of hematopoietic cell transplant, 40 years on. Hepatology 2010; 51: 1450–1460.

Umeda K Adachi S Tanaka S , GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantationet al. Comparison of continuous and twice‐daily infusions of cyclosporine a for graft‐versus‐host‐disease prophylaxis in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer 2015; 62: 291–298.

Flowers ME Inamoto Y Carpenter PA , et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214–3219.

Higman MA Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125: 435–454.

Lehrer J Brissot E Ruggeri A , et al. Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study. Bone Marrow Transplant 2018; 53: 231–233.

Gresch B Kirsch M Fierz K , et al. Medication nonadherence to immunosuppressants after adult allogeneic haematopoietic stem cell transplantation: a multicentre cross-sectional study. Bone Marrow Transplant 2017; 52: 304–306.

Ossenkoppele GJ Janssen JJ van de Loosdrecht AA. Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematologica 2016; 101: 20–25.

Takenaka K Nishida T Asano-Mori Y , et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan society for hematopoietic cell transplantation transplantation-related complication working group. Biol Blood Marrow Transplant 2015; 21: 2008–2016.

Fein JA Shimoni A Labopin M , et al. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia 2018; 32: 1787–1794.

Sorror ML Maris MB Storb R , et al. 170 Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.